The Oncology Care Model (OCM) is a Federal health reform program that aims to change the way cancer care in America is delivered. Its goal? To provide high quality, well-coordinated cancer care to patients while reducing costs for Medicare and beneficiaries. Eager to be involved in the future of cancer care, nearly
In 2015, Berkeley Research Group professionals published a white paper studying the impact of growth in the 340B program on the oncology marketplace.1 Our research found that 340B hospitals were playing an increasingly large role in oncology despite being a higher-cost site of care. Since then, the 340B program has grown an additional 67
1 Executive Summary Physician dispensing has been a critical part of the American healthcare system for decades, and dispensing physician practices have participated as in-network providers for various Medicare Part D pharmacy networks since the implementation of the Medicare Part D program in 2006. There is good reason for this. Receiving medication directly from
The complexity and cost of healthcare in this country is ever increasing. With an aging population, States around the country – including New York – continue to face complicated challenges in containing costs, while providing more efficient care. Nowhere has that borne out more than in the context of cancer care. Costs of cancer
1.0 OBJECTIVES Review the evolution of outpatient oncology practices and current shifts in site of oncology care Evaluate cost and outcome differences between outpatient hospital and community-based practices for breast, lung, and colorectal Understand the practical implications of cost and outcomes differences for key oncology stakeholders. 2.0 INTRODUCTION Access to affordable, high-quality cancer care
The dire consequences of having Pharmacy Benefit Managers (PBMs) within the United States’ health care system continue to be seen, especially by the millions of cancer patients across the nation who must interact with them to access life-saving drugs. Initially established as a way for insurance companies to outsource the management of drug benefits, PBMs
T here is no shortage of horror stories associated with the increasingly large role that Pharmacy Benefit Managers (PBMs) play in the United States’ health care system. With their numerous offshoots and service lines, PBMs have managed to take on an oligopolistic presence that adversely impacts patients receiving treatments, their health care providers, and everyone
There is growing awareness of the problems and pitfalls with Pharmacy Benefit Managers (PBMs) in the United States health care system. Contracted by insurance carriers to negotiate on their behalf with pharmaceutical companies, these ‘middle men’ corporations have quietly become an unavoidable part of our nation’s health care system. Controlling at least 80 percent
ABSTRACT Nearly 1.7 million new cancer diagnoses in the United States are projected for 2017. Controlling the cost of treating cancer is an important consideration for curbing the overall cost of health care. We conducted a systematic review of the literature on the cost of treating cancer in the two most common cancer treatment
Executive Summary Over the past year, an alarming trend has emerged in the healthcare context that threatens to disrupt the entire delivery model for a large subset of our nation’s most vulnerable patients – seniors enrolled in the Medicare Part D Program receiving complex medications for live-saving treatments. This trend – unilaterally-imposed by vertically-integrated
Resources
Initiatives
EVENTS
Get Involved
© Copyright Community Oncology Alliance | All Rights Reserved | Terms & Conditions | Privacy Policy
